Health
Eisai, Biogen Alzheimer’s Drug Denied by European Regulators
This article is for subscribers only.
European drug regulators rejected an Alzheimer’s therapy from Eisai Co. and Biogen Inc., a blow to the companies seeking to expand sales in one of the world’s biggest drug markets.
The European Medicines Agency’s human medicines committee recommended against granting marketing authorization for the companies’ drug, Leqembi. Its effect on delaying cognitive decline “does not counterbalance the risk of serious side effects associated with the medicine,” the committee said Friday in a statement.